As of December 2025, there are no peer-reviewed trials directly examining whether a GLP-1 agonist helps or harms exercise performance in athletes
Key takeaways Semaglutide is a weekly injectable medication for type 2 diabetes, obesity, and some forms of heart disease, administered subcutaneously in the stomach, thigh, or upper arm
Jan 7, 2023, The New York Times
(An active ingredient is what makes a medication work.) Semaglutide belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists
According to the product sheet: Pharmaceutical grade and therapeutically dosed stimulates release of fatty acids from adipose tissue assists transport of fats into mitochondria the cells energy furnace. (See your uploaded sheet) What the evidence says A small human trial of Coleus forskohlii (the herb containing forskolin) reported reductions in body fat in men over 12 weeks: Henderson S et al 2005 found a modest effect
Some people who experience zero fatigue still achieve significant weight loss